Entera Bio (NASDAQ:ENTX) Shares Gap Up - Time to Buy?

Key Points

• Entera Bio shares opened higher but later traded down 3.3%, last changing hands near $2.99 after closing at $3.03. The company has a market capitalization of approximately $509 million and remains unprofitable.
• Analyst views are mixed: Leerink Partners initiated coverage with an “outperform” rating, while other firms maintain buy or sell ratings. The consensus rating is “Hold”, with an average price target of $9.00.
• Entera Bio reported a quarterly loss of $0.14 per share, missing the $0.08 consensus loss estimate. The biotechnology company is developing oral versions of injectable protein and peptide therapies, including candidates for osteoporosis and hypoparathyroidism.

Shares of Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $3.03, but opened at $3.14. Entera Bio shares last traded at $2.9850, with a volume of 42,396 shares traded.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Leerink Partners began coverage on Entera Bio in a research note on Friday. They set an "outperform" rating and a $9.00 price objective for the company. Wall Street Zen upgraded Entera Bio to a "sell" rating in a report on Saturday, August 8th. HC Wainwright restated a "buy" rating on shares of Entera Bio in a research note on Wednesday, June 24th. Weiss Ratings reissued a "sell (d-)" rating on shares of Entera Bio in a report on Friday, July 17th. Finally, UBS Group set a $9.00 price objective on Entera Bio in a research note on Friday. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $9.00.

Entera Bio Trading Down 3.3%

The stock has a 50 day moving average price of $2.77 and a two-hundred day moving average price of $1.81. The company has a market cap of $509.32 million, a price-to-earnings ratio of -8.37 and a beta of 1.38.

Entera Bio (NASDAQ:ENTX - Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.06).

Institutional Investors Weigh In On Entera Bio

A hedge fund recently raised its position in Entera Bio stock. Renaissance Technologies LLC grew its holdings in shares of Entera Bio Ltd. (NASDAQ:ENTX - Free Report) by 338.4% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 473,442 shares of the company's stock after purchasing an additional 365,441 shares during the quarter. Renaissance Technologies LLC owned about 0.96% of Entera Bio worth $526,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 14.11% of the company's stock.

Entera Bio Company Profile

Entera Bio Ltd. is a biotechnology company developing orally administered therapies based on large-molecule drugs, including proteins and peptides that are traditionally delivered by injection. The company's proprietary delivery technology is designed to help these molecules pass through the gastrointestinal tract and reach the bloodstream, with the goal of improving convenience and patient adherence.

Entera Bio's lead programs have focused on bone and mineral disorders. Its pipeline has included EB613, an oral formulation of parathyroid hormone (PTH 1-34, or teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral PTH product candidate intended for hypoparathyroidism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.